Navigation Links
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Date:3/12/2009

sults, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual results to differ materially from current expectations include, but are not limited to:

  • our ability to borrow additional amounts under the loan agreement, which is subject to the discretion of the Lender;
  • our ability to obtain necessary financing in the near term, including amounts necessary to repay the loan by the September 14, 2009 maturity date;
  • our ability to control our operating expenses;
  • our failure to timely recruit and enroll patients for the FDG-PET clinical trial, as well as any future clinical trial;
  • our failure to obtain sufficient data from enrolled patients that can be used to evaluate VIA-2291, thereby impairing the validity or statistical significance of our clinical trials;
  • our ability to successfully complete our clinical trials of VIA-2291 on expected timetables and the outcomes of such clinical trials;
  • complexities in designing and implementing cardiovascular clinical trials using histological examinations, measurement of biomarkers, medical imaging and atherosclerotic plaque bioassays;

  • '/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
2. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
3. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
4. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
5. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
6. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
7. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
8. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... WI (PRWEB) November 23, 2014 ... and supplier of fine chemical ingredients to the ... the launch of its new website, Apiscent.com. , ... of Apiscent Labs, clean design, easy navigation, rotating ... make Apiscent Labs stand out. , ...
(Date:11/22/2014)... Colo. (PRWEB) November 21, 2014 ... proprietary cloud based analytics and scientific testing methodologies relating ... commitment for a $750,000 line of credit from an ... extremely pleased to have secured this commitment from one ... Executive Officer of CannLabs. “This capital will help accelerate ...
(Date:11/22/2014)... Respiratory therapy students will soon ... of life-like respiratory ailments using the latest in ... Rapids-based, Michigan Instruments Inc. developers of the world-renowned ... respiratory simulation units to the pro-gram, which cost ... Muskegon Community College are collaborating to offer Muskegon’s ...
(Date:11/21/2014)... England , Nov. 21, 2014   TRU-D SmartUVC ... will feature their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, ... this week from Nov. 23 to 26 at Stand 23. ... is the United Kingdom,s largest infection-related ... infection prevention societies to one of the leading events of ...
Breaking Biology Technology:CannLabs Secures $750,000 Line Of Credit 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 2Michigan Instruments Donates Two Respiratory Simulation Training and Test Lung (TTL) Devices to Grand Valley State University 3TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3
... May 15 Senetek PLC (OTC Bulletin Board: SNKTY), ... technologies that target the science of healthy aging, announced ... developments is now available by calling 877-SENETEK in the ... "We are pleased to provide this service to our ...
... Genetics, Inc. (NYSE Amex: ILI ) announced today ... Forum on Wednesday, May 20, 2009, at 2:40 p.m. EDT ... GA. Lewis H. Bender, Chief Executive Officer, will present an ... available genetic tests and recent milestones. "Genetic testing and personalized ...
... N.C., May 15 PRA International, a ... the annual meeting for the International Society for Pharmacoeconomics ... Experts from PRA,s Late Phase Services group will ... PRA,s capabilities. PRA,s Late Phase Services group supports ...
Cached Biology Technology:Senetek PLC Investor Hotline Goes Live 2Interleukin Genetics to Present at the 2009 BIO Business Forum 2PRA International Participating in Pharmacoeconomics and Outcomes Research Conference 2
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
(Date:11/15/2014)... we may still be a few years away from the ... gain instant access to all that ailed his patients, mobile ... for monitoring and measuring our health are cropping up in ... tad Orwellian to some, but a new survey suggests that ... into their healthcare regime. These are some of ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... coming up with ways to repair the human body, ... and ceramic substitutes ?but the body does not always ... universities have found that simply changing the surface texture ... a wide variety of materials. , Two recent ...
... how much they had already eaten -- in this case, ... who had no such environmental cues, finds a new Cornell ... eating at a table where leftover bones accumulated compared with ... than for women. , "The results suggest that people ...
... Virginia-Maryland Regional College of Veterinary Medicine (VMRCVM) at ... modified variant of Avian Newcastle disease virus (NDV) ... Elankurmaran Subbiah, assistant professor in the Department of ... research grant by the Department of Defense. This ...
Cached Biology News:Nanotextured implant materials: blending in, not fighting back 2Nanotextured implant materials: blending in, not fighting back 3Veterinary scientists explore poultry virus as cancer killer 2
... RNase Inhibitor (patent pending) is a protein ... binds and inhibits the most common and ... 1 and T1. SUPERaseIn can be used ... be problematic. It is ideal for in ...
... recombinant protein that has been shown to help ... of cDNA by reverse transcription, in vitro RNA ... Safe Inhibitor tightly binds RNases in a 1:1 ... RNases such as RNase A, RNase B, RNase ...
... RNase Inhibitor (Ribonuclease inhibitor) ... enzyme used to inhibit RNase ... DNase or endonuclease activity. , ... degradation of RNA template ...
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
Biology Products: